Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Britain authorises temporary use of flu vaccine to help meet demand

Published 22/10/2020, 16:09
Updated 22/10/2020, 16:20
© Reuters. FILE PHOTO: Start of the seasonal influenza vaccination campaign in France

© Reuters. FILE PHOTO: Start of the seasonal influenza vaccination campaign in France

LONDON (Reuters) - Britain has authorised the temporary use of the Flublok flu vaccine and ordered millions of doses as it seeks to give jabs to more people during the coronavirus pandemic.

A surge in demand for vaccines to ward off winter flu has led to shortages in some European cities, raising the risk of a potentially lethal "twindemic" as COVID-19 cases spike.

Britain is targeting the vaccination of more than 30 million people, nearly half the population, and said it had given authorisation for the supply of Flublok, which has been used in the United States for the last three winters.

"Flublok has been in regular use in the United States – and the evidence shows that it is an excellent product," deputy Chief Medical Officer Jonathan Van Tam said.

"I want to reassure everyone that all vaccines have undergone robust clinical trials and rigorous checks by the regulator to ensure they are safe, effective and of a high quality."

Flublok received authorisation for temporary supply from the Medicines and Healthcare products Regulatory Agency (MHRA).

The MHRA has the power to take such a step when it is satisfied that a medicine is safe and effective in response to a public health threat.

© Reuters. FILE PHOTO: Start of the seasonal influenza vaccination campaign in France

The regulator has been given extra powers during the course of the pandemic, such as being able also to temporarily authorise any coronavirus vaccine that meets safety and quality standards before it has received a full licence.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.